COVID-19 vaccine challenges: What have we learned so far and what remains to be done?

Abstract

Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed.

Cited by papers we hold 5

• Prevalence of Anxiety and Depression Among the General Population in Africa During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis · 2022
  Not checked
• A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
  No notice
• Anticoagulation as a therapeutic strategy for hospitalised patients with COVID-19 · 2022
  Not checked
• Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
  No notice
• Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review · 2021
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.